Clinical trial
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
NCT00028535
Study timeline
Study start (unknown)2001-11-01Date precision: month
Registry last updated2013-06-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Male Breast Cancerunresolved
Recurrent Breast Cancerunresolved
Recurrent Endometrial Carcinomaunresolved
Recurrent Gastric Cancerunresolved
Recurrent Non-small Cell Lung Cancerunresolved
Recurrent Ovarian Epithelial Cancerunresolved
Recurrent Small Cell Lung Cancerunresolved
Interventions
trastuzumabBIOLOGICAL
paclitaxelDRUG · verified · RxNorm: paclitaxel
recombinant interleukin-12BIOLOGICAL
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00028535 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.